Select Page

South Delhi Pharma, New Delhi, India

BLINCYTO (blinatumomab) for injection. FDA-Approved. To treat ALL

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

BLINCYTO (blinatumomab) for injection is a prescription medicine. BLINCYTO (blinatumomab) for injection is used to treat acute lymphoblastic leukemia (ALL) and Relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
INDICATIONS AND USAGE
BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with:

  • B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
  • Relapsed or refractory B-cell precursor acute lymphoblastic leukemia

DOSAGE FORMS & STRENGTHS
For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution.
Manufactured By: Amgen Inc
Prescribing Information URL: Click Here
South Delhi Pharma facilitate the supply of “BLINCYTO (blinatumomab) for injection FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.

Categories: ,

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

6 + 1 =

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.